Pharnext drug shows promise in neurological disease with no treatment

December 18, 2014 1:00 AM

3 0

(Reuters) - Using technology gleaned from the mapping of the human genome, privately held French drug developer Pharnext SAS is a step closer to providing a treatment for a rare neurological disorder called Charcot-Marie-Tooth (CMT) disease, for which no pharmaceutical therapy exists.

The company on Wednesday said its three-drug combination, currently known as PXT-3003, led to a 14.4 percent improvement compared with placebo on a scale used to evaluate disability of the upper and lower limbs in an 80-patient mid-stage study.

Read more

To category page